Newamsterdam Pharma N V 's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by intense competition and rapid innovation. Competitors include large pharmaceutical companies, smaller biotechnology and specialty pharmaceutical firms, and generic drug manufacturers. These competitors often possess greater financial and technical resources, as well as more experience in product discovery, development, regulatory approvals, and commercialization. The company expects to face increasing competition as new drugs and advanced technologies are introduced. Additionally, the development of new treatment methods may render the company's product candidates non-competitive or obsolete. For the company's obicetrapib product candidate, key competitive factors include enhanced LDL-lowering capability, tolerability, oral dosing convenience, reimbursement availability, and effects on disease risk predictors.
August 2, 2024
: NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company focused on developing non-statin therapeutics for cardiovascular disease (CVD), continues to make significant strides in its research and corporate strategies. This article discusses two important aspects of the company’s recent activities: the implementation of inducement share options under Nasdaq listing rules and the ongoing clinical trials evaluating the efficacy of its lead candidate, obicetrapib. With the rising prevalence of CVD, particularly in patients with elevated low-density lipoprotein cholesterol (LDL-C) who have not responded effectively to existing therapies, NewAmsterdam Pharma s innovations represent a critical in...
June 7, 2024
NAARDEN, the Netherlands and MIAMI, June 07, 2024 NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), an advanced-stage clinical biopharmaceutical company, has made a significant stride in bolstering its workforce. The company, renowned for developing oral, non-statin medications aimed at reducing cardiovascular disease (CVD) risk linked to elevated low-density lipoprotein cholesterol (LDL-C), has recently approved the grant of inducement share options to five new non-executive hires. This move underscores the company’s commitment to both clinical innovation and strategic talent acquisition.The Compensation Committee of NewAmsterdam’s Board of Directors has sanctioned the inducement share options for the...
March 25, 2024
NewAmsterdam Pharma to Present Promising Findings at the 2024 American College of Cardiology Congress: Combining Obicetrapib and Ezetimibe Shows Potential in Reducing Cardiovascular Risks Associated with Elevated LDL CholesterolNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company), a leading clinical biopharmaceutical company specializing in oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), has recently announced that it will unveil new data from the Phase 2 ROSE2 clinical trial at the highly anticipated 2024 American College of Cardiology Congress (ACC). Taking place in Atlanta, Georgia, from Ap...
Publicly Traded Peers of Newamsterdam Pharma Company N v
Sources:
Newamsterdam Pharma Company N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Newamsterdam Pharma Company N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
